ICD-10 · PDGM grouping
C88 Malignant immunoproliferative diseases and certain other B-cell lymphomas
All 12 codes in the C88 family, with the PDGM clinical group, comorbidity subgroup and primary-position rule CMS assigns, read from the CMS grouper crosswalk v07.2.26 and the CDC FY2027 code file.
Codes in family
12
Can lead a claim
12
Cannot lead a claim
0
What CMS assigns to C88
All 12 codes group to MMTA - Infectious Disease, Neoplasms, and Blood-Forming Diseases. Comorbidity subgroups: 10 toward Follicular and Other Non-Hodgkin’s Lymphoma, and Leukemia; 2 toward Non-Hodgkin’s Lymphoma. Every code can lead a claim.
- Follicular and Other Non-Hodgkin’s Lymphoma, and Leukemia
- Non-Hodgkin’s Lymphoma
Every code in C88
Descriptions are CDC’s FY2027 wording; where CMS’s grouper abbreviates one, its form is shown beneath.
| Code | Description | Primary position | Clinical group | Comorbidity subgroup |
|---|---|---|---|---|
| C88.0 Waldenstrom macroglobulinemia | ||||
| C88.00 | Waldenstrom macroglobulinemia not having achieved remission | Can lead a claim | K | Follicular and Other Non-Hodgkin’s Lymphoma, and Leukemia |
| C88.01 | Waldenstrom macroglobulinemia, in remission | Can lead a claim | K | Follicular and Other Non-Hodgkin’s Lymphoma, and Leukemia |
| C88.2 Heavy chain disease | ||||
| C88.20 | Heavy chain disease not having achieved remission | Can lead a claim | K | Follicular and Other Non-Hodgkin’s Lymphoma, and Leukemia |
| C88.21 | Heavy chain disease, in remission | Can lead a claim | K | Follicular and Other Non-Hodgkin’s Lymphoma, and Leukemia |
| C88.3 Immunoproliferative small intestinal disease | ||||
| C88.30 | Immunoproliferative small intestinal disease not having achieved remissionCMS: Immunoproliferative small intestinal disease not remission | Can lead a claim | K | Follicular and Other Non-Hodgkin’s Lymphoma, and Leukemia |
| C88.31 | Immunoproliferative small intestinal disease, in remission | Can lead a claim | K | Follicular and Other Non-Hodgkin’s Lymphoma, and Leukemia |
| C88.4 Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma] | ||||
| C88.40 | Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma] not having achieved remissionCMS: Extrnod mrgnl B-cell lymph mucosa-assoc lym tiss not remis | Can lead a claim | K | Non-Hodgkin’s Lymphoma |
| C88.41 | Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma], in remissionCMS: Extrnod mrgnl B-cell lymph mucosa-assoc lym tiss, in remis | Can lead a claim | K | Non-Hodgkin’s Lymphoma |
| C88.8 Other malignant immunoproliferative diseases | ||||
| C88.80 | Other malignant immunoproliferative diseases not having achieved remissionCMS: Other malignant immunoproliferative diseases not remission | Can lead a claim | K | Follicular and Other Non-Hodgkin’s Lymphoma, and Leukemia |
| C88.81 | Other malignant immunoproliferative diseases, in remission | Can lead a claim | K | Follicular and Other Non-Hodgkin’s Lymphoma, and Leukemia |
| C88.9 Malignant immunoproliferative disease, unspecified | ||||
| C88.90 | Malignant immunoproliferative disease, unspecified not having achieved remissionCMS: Malignant immunoproliferative disease, unsp not remission | Can lead a claim | K | Follicular and Other Non-Hodgkin’s Lymphoma, and Leukemia |
| C88.91 | Malignant immunoproliferative disease, unspecified, in remissionCMS: Malignant immunoproliferative disease, unsp, in remission | Can lead a claim | K | Follicular and Other Non-Hodgkin’s Lymphoma, and Leukemia |
Sources: CMS HH PPS Grouper Software v07.2.26, effective 2026-10-01, for the clinical group, comorbidity subgroup, code-first conventions and primary-position flags; CDC NCHS ICD-10-CM FY2027 code descriptions for the family title and code wording. This is the crosswalk Medicare runs a claim through. Grouping also depends on admission source, timing, the OASIS functional items and the rest of the diagnosis list.
The monthly home health regs digest
What CMS changed, what's due next, and what to do about it — one email a month, no fluff. Read the first issue